BRAF


Also found in: Acronyms.

BRAF

A gene on chromsome 7q34 that encodes a protein of the raf/mil family of serine/threonine protein kinases, which plays a role in regulating the MAP kinase/ERKs-signalling pathway, affecting cell division, differentiation and secretion.

Molecular pathology
BRAF mutations are associated with cardiofaciocutaneous syndrome, which is characterised by heart defects, mental retardation and a distinctive facial appearance. Acquired BRAF mutations have been linked to non-Hodgkin lymphoma, colorectal cancer, melanoma, thyroid carcinoma, non-small cell lung carcinoma and adenocarcinoma of lung.
References in periodicals archive ?
DNA tissue was extracted from stored samples of tumor tissue so that BRAF status could be determined.
The just-approved THxID BRAF test will be used to determine if the mutations are present.
The FDA approved vemurafenib for the treatment of metastatic melanoma with the BRAF (V660E) mutation on August 17, 2011.
In a phase 3 randomized clinical trial, which included 675 patients with previously untreated metastatic melanoma harboring the BRAF V600E mutation, vemurafenib was compared with dacarbazine (DTIC-Dome, originally marketed by Bayer), a well-established first-line chemotherapy in metastatic melanoma.
The cobas BRAF test will play a critical role in improving treatment for metastatic melanoma, one of the most aggressive and deadly cancers.
We are interested in addressing the question of whether carrying certain variants of the BRAF gene could predispose people to having or developing more moles, and thus to an increased risk of developing melanoma," says principal investigator Claus Garbe.
Most of the mutations in BRAF alter its protein so that it continuously prods cells with a growth signal.
These data represent the longest follow-up of any cohort of patients treated with any BRAF inhibitor.
M2 PHARMA-November 8, 2017-FDA Approves Zelboraf for Erdheim-Chester Disease with BRAF V600 Mutation
The US Food and Drug Administration (FDA) has granted Novartis (VTX: NOVN) Breakthrough Therapy Designation (BTD) for Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection, the company disclosed on Tuesday.
Novartis today announced results from a Phase III study of 870 patients with stage III BRAF V600E/K mutation-positive melanoma after complete surgical resection treated with the combination of Tafinlar (dabrafenib) + Mekinist (trametinib) .
Combination therapy to inhibit the MAP kinase pathway is associated with a median overall survival of more than 2 years for patients with metastatic melanoma positive for the BRAF V600 mutation who have not previously received a BRAF inhibitor.